+68.6%
CSX vs GSK
+63.2%
+5.4%
-29.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.4% | -0.2% | -3.2% | -3.3% |
| 7D | -5.5% | +1.7% | -7.2% | -5.8% |
| 30D | +4.9% | +7.0% | -2.1% | +4.0% |
| 3M | -2.9% | -2.7% | -0.2% | -2.6% |
| 6M | +8.3% | +1.4% | +6.9% | +7.9% |
| YTD | +36.7% | +5.3% | +31.4% | +35.8% |
| 1Y | +41.5% | +10.6% | +30.9% | +39.8% |
| 3Y | +68.6% | +62.6% | +6.0% | +49.6% |
| All | +68.6% | +63.2% | +5.4% | +49.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling